readthroughSign in
Nov 16, 2026Quarterly update

Acrivon adds immunology pillar, reports Q3 2026 results and ACR-2316 data ahead

Acrivon acquired a JAK1 inhibitor and a preclinical PKCθ program while reporting $77.8 million in cash expected to fund operations into the fourth quarter of 2027.

Acrivon Therapeutics said immunology and inflammation has become a second strategic pillar for the company, which it considers well-suited for its AP3 precision medicine approach.1 The company said it acquired ACR-525 after identifying it as a potentially best-in-class JAK1 inhibitor using its AI-driven AP3 platform for extensive profiling head-to-head against approved JAK inhibitors and dupilumab.1 Eosinophilic esophagitis is targeted as the first indication for the Phase 2-ready, oral, highly selective JAK1 inhibitor.1 The acquisition also included a preclinical PKCθ program aimed at T-cell driven immunology and inflammation disorders.1

On the oncology side, Acrivon said early Phase 1/2 results for ACR-2316, its WEE1/PKMYT1 inhibitor, will be presented as a late-breaking oral plenary presentation by Dr. Tim Yap at the upcoming Tri-Meeting.1 The company reported a favorable safety profile and long-lasting clinical benefit across AP3-predicted tumors during dose escalation, including heavily pretreated lung cancers with patients on treatment for over 73 weeks and a confirmed complete response.1 ACR-2316 is also set to be tested in pancreatic ductal adenocarcinoma, based on public data showing WEE1 is synthetic lethal in a K-Ras and p53 mutated context.1

For ACR-368, the company's CHK1/2 inhibitor, Acrivon said a prespecified interim analysis of the Phase 2 registrational-intent trial remains on track.1 The company also said it nominated ACR-7280, a potential first-in-class oral CDK11 inhibitor identified through AP3, to advance into IND-enabling studies for development in AML.1

Financially, Acrivon reported cash, cash equivalents and investments of $77.8 million as of September 30, 2026, which it expects will fund operating expenses and capital expenditures into the fourth quarter of 2027.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.